- Home
- NUVL vs NBIS Comparison
NUVL vs NBIS Comparison
Compare NUVL & NBIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- NBIS
- Stock Information
- Founded
- NUVL 2017
- NBIS 2000
- Country
- NUVL United States
- NBIS Netherlands
- Employees
- NUVL N/A
- NBIS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- NBIS
- Sector
- NUVL Health Care
- NBIS
- Exchange
- NUVL Nasdaq
- NBIS NYSE
- Market Cap
- NUVL 5.6B
- NBIS 4.8B
- IPO Year
- NUVL 2021
- NBIS 2011
- Fundamental
- Price
- NUVL $75.00
- NBIS $47.97
- Analyst Decision
- NUVL Strong Buy
- NBIS Strong Buy
- Analyst Count
- NUVL 8
- NBIS 3
- Target Price
- NUVL $115.50
- NBIS $60.67
- AVG Volume (30 Days)
- NUVL 452.9K
- NBIS 16.3M
- Earning Date
- NUVL 08-07-2025
- NBIS 07-30-2025
- Dividend Yield
- NUVL N/A
- NBIS N/A
- EPS Growth
- NUVL N/A
- NBIS N/A
- EPS
- NUVL N/A
- NBIS N/A
- Revenue
- NUVL N/A
- NBIS $161,400,000.00
- Revenue This Year
- NUVL N/A
- NBIS $38,469.36
- Revenue Next Year
- NUVL N/A
- NBIS $106.37
- P/E Ratio
- NUVL N/A
- NBIS N/A
- Revenue Growth
- NUVL N/A
- NBIS N/A
- 52 Week Low
- NUVL $55.54
- NBIS $14.09
- 52 Week High
- NUVL $113.51
- NBIS $55.04
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- NBIS N/A
- Support Level
- NUVL $76.42
- NBIS N/A
- Resistance Level
- NUVL $78.94
- NBIS N/A
- Average True Range (ATR)
- NUVL 2.71
- NBIS 0.00
- MACD
- NUVL -0.34
- NBIS 0.00
- Stochastic Oscillator
- NUVL 31.73
- NBIS 0.00
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.